West Virginia union leaders call on lawmakers to stabilize PEIA costs
Kristie Skidmore, president of the AFT-WV, and Dale Lee, president of the West Virginia Education Association, speak during a press conference on Wednesday, Feb. 26, 2025. The union leaders are calling on lawmakers to stabilize the costs of PEIA. (Lori Kersey | West Virginia Watch)
Union leaders representing West Virginia's public workers on Wednesday once again called on lawmakers to come up with solutions to stabilize the rising costs of health care coverage for state employees.
Representatives of six unions held a joint news conference at the state Culture Center in Charleston, just across the state Capitol Complex from where lawmakers are conducting business as part of the regular legislative session.
'We're asking the Legislature to do what the Legislature said they would do and what they're obligated to do, and to stabilize [the Public Employees Insurance Agency] for the public employees in the state of West Virginia,' said Joe White, executive director of the West Virginia School Service Personnel Association.
'Folks, PEIA is a benefit. It was promised to the public employees in the state of West Virginia,' he said. 'Pay your bills, pay for the insurance for the public employees that serve the great state of West Virginia.'
In December 2024, the PEIA finance board approved premium increases for fiscal year 2026 of 14% for state employees and 16% for local local government employees in addition to out of pocket and copay increases. The fiscal year starts in July. The agency will also raise premiums by 12% for retirees.
Agency officials have said that rising health care costs, particularly inflation for prescription GLP-1 drugs that treat obesity and diabetes, are a major driver of the rate increases.
White illustrated the PEIA cost increases over the last few years using Harrison County as an example. One employee saw the costs of PEIA rise from $2,876 in 2023 to a projected $8,152 in 2026, not including increases in co-pays, prescription costs and deductibles, he said.
While Gov. Patrick Morrisey called on lawmakers in his State of the State address to work with him on long and short-term solutions for PEIA, Josh Sword, president of the ALF-CIO, said he had not seen a budget bill with an amount of money for PEIA that would make the program right.
'I want to see, personally, and I think I can speak on behalf of the folks behind me, PEIA become a priority when it comes to budgeting,' Sword said. 'Both the governor's office and both chambers of the Legislature. If they do that, then I think we have a real opportunity to get to a place we all agree. Unless that happens, I have real concern.'
During a budget hearing Wednesday morning, PEIA acting director Jason Haught echoed previous comments from former director Brian Cunningham that the inflation of prescription drugs costs are driving the cost increases for PEIA. Haught said the country needs to set a fixed rate for pharmaceuticals the way that hospital and physician services rates are fixed.
'[Pharmaceutical] manufacturers get to set the list price of whatever amount they want, and there's no regulation on that list pricing,' he said. 'So I think that has produced some unsustainable cost trends to the healthcare marketplace.'
The agency expects its costs to rise by 60% over the next five years, driven primarily by the cost of prescription drugs. The state's health is also a factor, he said.
'At the end of the day, if you don't want health care costs, you've got to have a healthy population,' Haught said. 'Unfortunately, we're sick and old. That does not translate to an easily solved health care cost in this state. That's your bottom line, I think. We need to get younger and we need to get healthier. That's going to reduce that trend.'
So far, six bills concerning PEIA have been introduced in the House and three in the Senate. Proposals have included abolishing and privatizing the health insurance plan. Another bill would make PEIA into a health savings account.
Elaine Harris, the international staff representative for district 213 of the Communications Workers of America, spoke against privatizing PEIA.
'Folks. That's not the answer,' she said. 'PEIA is not a for-profit plan. It is money in on premiums and the way that the agency makes all of the dollars work, and then it's money out, paying claims, paying for the high cost of drugs.'
Harris said the state and the federal governments need to address the high costs of drugs.
Dale Lee, president of the West Virginia Education Association, said that this year there are more than 1,500 unfilled teaching positions across the state without a certified teacher. He predicted that the number of unfilled positions would increase in years to come, as teachers leave the state for better benefits and pay.
'I've heard Gov. Morrisey say that he wants to make our salaries competitive with other states,' he said. 'That is important, but just as important is to stabilize PEIA.'
Union leaders asked state lawmakers to implement some of the policy recommendations that came from a 2018-2019 task force formed after the teachers strike. None of the recommendations 'ever saw the light of day,' Lee said.
'I'm calling upon everyone to get us back to the table,' Lee said. 'Let's come back to the table. There are things that we can do to help stabilize this plan, but the important part is we have to be at the table. That's what I'm asking that the Legislature, the governor, do. Bring us back, and let's figure out this plan in a way that makes sense.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Iowa Republican Jim Carlin announces primary campaign against Joni Ernst for US Senate
Iowa Republican Jim Carlin is launching a primary campaign against incumbent Republican U.S. Sen. Joni Ernst, saying the two-term senator has failed to deliver on her famous "make 'em squeal" mantra. 'Joni Ernst said she would go to D.C. and make them squeal,' Carlin said in a statement, referring to a viral campaign ad that helped propel Ernst to her first term in 2014. 'After a decade, it's clear it was a clever campaign commercial, not conviction. Rather than making them squeal, Joni has joined The Swamp." Carlin is a former state senator and trial lawyer who served in the Iowa Legislature from 2017 to 2022. He is the founder of the Iowa Liberty Network, a group focused on "maintaining the liberties endowed by our Creator through getting authentic, constitutional conservatives elected to the state legislature and other public offices," according to its website. Carlin previously mounted a primary campaign against Iowa's other Republican U.S. senator, Chuck Grassley, in 2022. He positioned himself to the right of Grassley, arguing he was more conservative on issues such as immigration and the Second Amendment, and he criticized Grassley for voting to certify the 2020 election in Democrat Joe Biden's favor without pushing to investigate unsubstantiated allegations of fraud. Grassley defeated him 73.5% to 26.5%. "Senator Ernst has a proven record of conservative leadership — cutting waste, securing the border, and making Washington squeal to keep Iowans' hard-earned money in their own pockets," Ernst's campaign manager Bryan Kraber said in a statement. "And she delivers for our families, farmers and veterans. Iowans already saw through Carlin's last failed campaign, and they'll reject his desperate attempt at relevance again in 2026.' Carlin said in a news release that Ernst pledged to serve just two terms in the U.S. Senate when she first ran in 2014, even though she is now seeking a third term. And he said she angered "America First conservatives" with her reluctance to support Republican President Donald Trump's pick to lead the U.S. Department of Defense, Pete Hegseth. Ernst ignited a firestorm among Republicans by withholding her support for Hegseth initially, although she ultimately voted to confirm him. Carlin also pointed to Ernst's 2022 vote for the Respect for Marriage Act, which garnered intense pushback from some Iowa Republicans. At least 17 county parties voted to condemn or censure Ernst over the vote. 'Iowans deserve a voice in Washington, D.C., who actually listens to them and represents them — not big donors and special interests,' he said. 'More than that, Iowans deserve someone who genuinely cares about them and will work to make their lives better. There are enough self-serving establishment politicians in Washington. President Donald J. Trump needs America First allies, not adversaries.' Ernst has not formally announced her reelection effort, but she has hired a campaign manager and scheduled her annual Roast and Ride fundraiser for the fall. One other Republican challenger, Joshua Smith, has announced a campaign against Ernst for the GOP nomination. And two Democrats have formally entered the race: Knoxville Chamber of Commerce director Nathan Sage and State Rep. J.D. Scholten of Sioux City. State Sen. Zach Wahls, D-Coralville, and state Rep. Josh Turek, D-Council Bluffs, have also previously said they are considering running. Brianne Pfannenstiel is the chief politics reporter for the Des Moines Register. Reach her at bpfann@ or 515-284-8244. Follow her on X at @brianneDMR. This article originally appeared on Des Moines Register: Joni Ernst gets primary challenge from Iowa Republican Jim Carlin
Yahoo
an hour ago
- Yahoo
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada: musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $28 per share, up 47% from the $19 per share the stock was initially priced at. Read more about Omada's opening stock moves and today's market action. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept that Duffy and his co-founders realized was needed more than a decade ago when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic, when digital health was experiencing an investment boom, he said no and added that the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. "We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis," the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. "We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively." Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada: musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $28 per share, up 47% from the $19 per share the stock was initially price at. Read more about Omada's opening stock moves and today's market action. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept that Duffy and his co-founders realized was needed more than a decade ago when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic when digital health was experiencing an investment boom, he said no and added that the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. 'We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis,' the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. 'We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively.' Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Sign in to access your portfolio